TABLE 1.
Gastric cancer patients’ demographic characteristics and PSAT1 expression.
| Characteristic | Low expression of PSAT1 (n = 187) | High expression of PSAT1 (n = 188) | p value |
|---|---|---|---|
| Age, n (%) | 0.032 | ||
| ≤65 | 93 (25.1%) | 71 (19.1%) | |
| >65 | 93 (25.1%) | 114 (30.7%) | |
| Gender, n (%) | 0.073 | ||
| Female | 58 (15.5%) | 76 (20.3%) | |
| Male | 129 (34.4%) | 112 (29.9%) | |
| T stage, n (%) | 0.471 | ||
| T1 | 10 (2.7%) | 9 (2.5%) | |
| T2 | 38 (10.4%) | 42 (11.4%) | |
| T3 | 90 (24.5%) | 78 (21.3%) | |
| T4 | 44 (12%) | 56 (15.3%) | |
| N stage, n (%) | 0.638 | ||
| N0 | 58 (16.2%) | 53 (14.8%) | |
| N1 | 49 (13.7%) | 48 (13.4%) | |
| N2 | 35 (9.8%) | 40 (11.2%) | |
| N3 | 32 (9%) | 42 (11.8%) | |
| M stage, n (%) | 0.219 | ||
| M0 | 168 (47.3%) | 162 (45.6%) | |
| M1 | 9 (2.5%) | 16 (4.5%) | |
| Pathologic stage, n (%) | 0.112 | ||
| Stage I | 23 (6.5%) | 30 (8.5%) | |
| Stage II | 65 (18.5%) | 46 (13.1%) | |
| Stage III | 69 (19.6%) | 81 (23%) | |
| Stage IV | 16 (4.5%) | 22 (6.2%) | |
| Histologic grade, n (%) | 0.112 | ||
| G1 | 8 (2.2%) | 2 (0.5%) | |
| G2 | 64 (17.5%) | 73 (19.9%) | |
| G3 | 112 (30.6%) | 107 (29.2%) | |
| Primary therapy outcome, n (%) | 0.769 | ||
| PD | 35 (11%) | 30 (9.5%) | |
| SD | 9 (2.8%) | 8 (2.5%) | |
| PR | 1 (0.3%) | 3 (0.9%) | |
| CR | 116 (36.6%) | 115 (36.3%) | |
| Race, n (%) | 0.062 | ||
| Asian | 47 (14.6%) | 27 (8.4%) | |
| Black or African American | 4 (1.2%) | 7 (2.2%) | |
| White | 118 (36.5%) | 120 (37.2%) | |
| Histological type, n (%) | 0.028 | ||
| Diffuse Type | 40 (10.7%) | 23 (6.1%) | |
| Mucinous Type | 12 (3.2%) | 7 (1.9%) | |
| Not Otherwise Specified | 103 (27.5%) | 104 (27.8%) | |
| Papillary Type | 2 (0.5%) | 3 (0.8%) | |
| Signet Ring Type | 6 (1.6%) | 5 (1.3%) | |
| Tubular Type | 24 (6.4%) | 45 (12%) | |
| Residual tumor, n (%) | 0.867 | ||
| R0 | 144 (43.8%) | 154 (46.8%) | |
| R1 | 8 (2.4%) | 7 (2.1%) | |
| R2 | 7 (2.1%) | 9 (2.7%) |